Tyrosine kinase inhibitors are the standard treatment for gastrointestinal stromal tumours (GISTs) with oncogenic mutations in the KIT protooncogene (KIT) and the Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) genes [20]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.